REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 Prior to signing this Agreement, Licensee has provided to PHS the Commercial Development Plan at Appendix F, under which Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 2 contracts
Samples: Sublicense and License Agreement (Neopharm Inc), Sublicense and License Agreement (Neopharm Inc)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 9.1 Prior to signing this Agreement, Licensee has provided to PHS with the Commercial Development Plan at in Appendix FE, under which Licensee intends to bring Licensed Product(s) or Licensed Process(es) within the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are arc determined as specified in Appendix D.
Appears in 2 contracts
Samples: Patent License Agreement (Bavarian Nordic a/S / ADR), Patent License Agreement (Bavarian Nordic a/S / ADR)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 Prior to signing this Agreement, Licensee has provided to PHS the Commercial Development Plan at Appendix F, under which Licensee intends to bring the subject matter of the Licensed Patent Rights and/or Biological Materials to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.E.
Appears in 2 contracts
Samples: Patent License Agreement (Aridis Pharmaceuticals, Inc.), Patent License Agreement (Aridis Pharmaceuticals, Inc.)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 9.1 Prior to signing this Agreement, Licensee has provided to PHS with the Commercial Development Plan at referred to in more detail in Appendix FE, and under which Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.
Appears in 2 contracts
Samples: Patent License Agreement (Merrimack Pharmaceuticals Inc), Patent License Agreement (Merrimack Pharmaceuticals Inc)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 Prior to signing this Agreement, Licensee has provided to PHS the Commercial Development Plan at Appendix F, under which Licensee intends to bring the subject matter of the Licensed Patent Rights and/or Background Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D.E.
Appears in 1 contract
Samples: Public Health Service (Neopharm Inc)
REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS. 9.01 Prior to signing this Agreement, Licensee has provided to PHS the Commercial Development Plan at Appendix F, under which Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This The Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Performance and Benchmarks are determined as specified in Appendix D.E.
Appears in 1 contract
Samples: Patent License Agreement (Genencor International Inc)